Nektar Therapeutics NKTR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.7M-20.0% | $3.2M-67.5% | $11.35M+81.7% | $6.33M-38.9% | $7.12M+31.3% | ||
| $419.03M+133% | $230.64M+9.3% | $229.18M+6.9% | $132.92M-45.4% | $179.74M-25.3% | ||
| $589.04M+156% | $266.27M+1.9% | $281.36M-1.8% | $186.57M-36.8% | $229.91M-28.1% | ||
| $763.27M+198% | $280.41M-7.7% | $301.35M-2.1% | $207.53M-39.6% | $256.24M-35.3% | ||
| $10.03M-43.8% | $10.77M-6.8% | $15.56M+81.5% | $14.28M+121% | $17.83M+104% | ||
| $57.71M-18.6% | $53.54M-12.8% | $66.34M-1.8% | $71.39M+24.5% | $70.93M+35.3% | ||
| $187.06M-22.9% | $190.57M-21.6% | $216.26M-16.5% | $231.75M-12.1% | $242.5M-10.0% | ||
| 390M+30.0% | 390M+38,999,900% | 390M+30.0% | 300M0.0% | 300M0.0% | ||
| -$3.81B-4.3% | -$3.76B-4.6% | -$3.72B-3.4% | -$3.69B-3.4% | -$3.65B-3.8% | ||
| $576.22M+4,094% | $89.83M+47.9% | $85.09M+74.1% | -$24.21M-130% | $13.74M-89.2% | ||
| $763.27M+198% | $280.41M-7.7% | $301.35M-2.1% | $207.53M-39.6% | $256.24M-35.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Nektar Therapeutics cover its short-term obligations?
- Its current ratio is 10.21 — current assets exceed current liabilities.
- Where does Nektar Therapeutics's balance sheet data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.